This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eichenauer, D. A. Articles by Hansen, H. P. Search for Related Content PubMed PubMed Citation Articles by Eichenauer, D. A. Articles by Hansen, H. P.

ADAM10 Inhibition of Human CD30 Shedding Increases Specificity of Targeted Immunotherapy In vitro

¹ Department of Internal Medicine I and ² Center for Molecular Medicine, University Hospital Cologne, Cologne, Germany; ³ Department of Biochemistry, University of Kiel, Kiel, Germany; and ⁴ Ludwig Institute for Cancer Research, PO Royal Melbourne Hospital, Victoria, Melbourne, Australia

Requests for reprints: Hinrich Hansen, Department of Internal Medicine I, University Hospital Cologne, LFI, Ebene 4, Room 703, Kerpener Str. 62, 50924 Cologne, Germany. Phone: 49-221-478-5808; Fax: 49-221-478-3778; E-mail: h.hansen{at}uni-koeln.de.

CD30 is a transmembrane protein selectively overexpressed on many human lymphoma cells and therefore an interesting target for antibody-based immunotherapy. However, binding of therapeutic antibodies stimulates a juxtamembrane cleavage of CD30 leading to a loss of target antigen and an enhanced release of the soluble ectodomain of CD30 (sCD30). Here, we show that sCD30 binds to CD30 ligand (CD153)–expressing non-target cells. Because antibodies bind to sCD30, this results in unwanted antibody binding to these cells via sCD30 bridging. To overcome shedding-dependent damage of normal cells in CD30-specific immunotherapy, we analyzed the mechanism involved in the release. Shedding of CD30 can be enhanced by protein kinase C (PKC) activation, implicating the disintegrin metalloproteinase ADAM17 but not free cytoplasmic calcium. However, antibody-induced CD30 shedding is calcium dependent and PKC independent. This shedding involved the related metalloproteinase ADAM10 as shown by the use of the preferential ADAM10 inhibitor GI254023X and by an ADAM10-deficient cell line generated from embryonically lethal ADAM10^–/^– mouse. In coculture experiments, the antibody-induced transfer of sCD30 from the human Hodgkin's lymphoma cell line L540 to the CD30-negative but CD153-expressing human mast cell line HMC-1 was inhibited by GI254023X. These findings suggest that selective metalloproteinase inhibitors blocking antibody-induced shedding of target antigens could be of therapeutic value to increase the specificity and reduce side effects of immunotherapy with monoclonal antibodies. [Cancer Res 2007;67(1):332–8]

This article has been cited by other articles:

				S. J. Levine Molecular Mechanisms of Soluble Cytokine Receptor Generation J. Biol. Chem., May 23, 2008; 283(21): 14177 - 14181. [Abstract] [Full Text] [PDF]